Met antibody detects endogenous levels of Met only when phosphorylated at tyrosine 1234.
Aufreinigung
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Immunogen
The antiserum was produced against synthesized phosphopeptide derived from human Met around the phosphorylation site of tyrosine 1234 (K-E-YP-Y-S).
Western Blot: 1: 500approx. 1: 1000. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1.0mg/mL
Buffer
BPS(without Mg2+ and Ca2+), pH 7.4 containing 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
AUTS9 antikoerper, HGFR antikoerper, RCCP2 antikoerper, c-Met antikoerper, AI838057 antikoerper, HGF antikoerper, Par4 antikoerper, Hgfr antikoerper, c-met antikoerper, MET antikoerper, C-MET antikoerper, met antikoerper, met-A antikoerper, MET proto-oncogene, receptor tyrosine kinase antikoerper, met proto-oncogene antikoerper, MET proto-oncogene, receptor tyrosine kinase L homeolog antikoerper, MET antikoerper, Met antikoerper, met.L antikoerper
Hintergrund
C-Met, a member of the tyrosine kinase superfamily, is the receptor for hepatocyte growth factor, also known as scatter factor (HGF/SF). The mature c-Met protein is a disulfide-linked heterodimer with Mr=190 kDa composed of a heavily glycosylated alpha subunit that is completely extracellular in localization, and a beta subunit comprising an extracellular ligand binding domain, a single transmembrane domain, and a cytoplasmic tyrosine kinase domain. Cells expressing c-Met include epithelial cells, endothelial cells, blood cells of various types, and glomerular mesenchymal cells. HGF/SF binding to c-Met stimulates receptor dimerization and the phosphorylation of numerous residues within the receptor's cytoplasmic domain. Signaling proteins that are phosphorylated and/or localized in response to c-Met phosphorylation include: Grb2, Shc, Cbl, Crk, cortactin, paxillin, GAB1, PI3K, FAK, Src, Ras, ERK1 and 2, JNK, PLC gamma, AKT, and STAT3. HGF/SF stimulation of c-Met expressing cells enhances proliferation, migration, morphogenesis, and protease synthesis, characteristics that are associated with invasive cell phenotype. Many types of cancer exhibit sustained c-Met stimulation, overexpression, or mutation, including carcinomas of the colon, breast, ovary, lung, liver, prostate, thyroid, kidney, as well as melanomas and sarcomas. In addition to cancer studies, other research areas in which c-Met is under investigation include organogenesis, organ regeneration, angiogenesis and surgical wound healing.Synonyms: HGF/SF receptor, Hepatocyte growth factor receptor, MET, Met proto-oncogene tyrosine kinase, Scatter factor receptor, c-Met